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Abstract
Background: Urinary tract infections (UTI) are among the most prevalent microbial diseases and their financial burden
on society is substantial. The continuing increase of antibiotic resistance worldwide is alarming. Thus, well-tolerated,
highly effective therapeutic alternatives are urgently needed. Although there is evidence indicating that bacteriophage
therapy may be effective and safe for treating UTIs, the number of investigated patients is low and there is a lack of
randomized controlled trials.
Methods and design: This study is the first randomized, placebo-controlled, double-blind trial investigating
bacteriophages in UTI treatment. Patients planned for transurethral resection of the prostate are screened for UTIs and
enrolled if in urine culture eligible microorganisms ≥104 colony forming units/mL are found. Patients are randomized in a
double-blind fashion to the 3 study treatment arms in a 1:1:1 ratio to receive either: a) bacteriophage (i.e. commercially
available Pyo bacteriophage) solution, b) placebo solution, or c) antibiotic treatment according to the antibiotic sensitivity
pattern. All treatments are intended for 7 days. No antibiotic prophylaxes will be given to the double-blinded treatment
arms a) and b). As common practice, the Pyo bacteriophage cocktail is subjected to periodic adaptation cycles during the
study. Urinalysis, urine culture, bladder and pain diary, and IPSS questionnaire will be completed prior to and at the end
of treatment (i.e. after 7 days) or at withdrawal/drop out from the study. Patients with persistent UTIs will undergo
antibiotic treatment according to antibiotic sensitivity pattern.
Discussion: Based on the high lytic activity and the potential of resistance optimization by direct adaptation of
bacteriophages, and considering the continuing increase of antibiotic resistance worldwide, bacteriophage therapy is a
very promising treatment option for UTIs. Thus, our randomized controlled trial investigating bacteriophages for treating
UTIs will provide essential insights into this potentially revolutionizing treatment option.
Trial registration: This study has been registered at clinicaltrials.gov (www.clinicaltrials.gov/ct2/show/
NCT03140085). April 27, 2017.
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Background
Urinary tract infections (UTI) are highly prevalent and
put a substantial financial burden on the health care sys-
tems worldwide. In the USA alone, over 7 million phys-
ician consultations are due to UTIs [1], resulting in
estimated direct and indirect costs of 1.6 billion US dol-
lars [1]. Further, UTIs account for more than 100′000
hospital admissions annually [1], and for at least 40% of
all hospital-acquired infections [2]. The increasing threat
of antibiotic resistance, mainly due to uncritical use of
antibiotics [3, 4], and the subsequent absence of access
to effective antimicrobials constitutes a challenge for the
future [5]. As UTIs account for approximately 15% of all
community-prescribed antibiotics in the USA [6], they
play an important role for direct antibiotic selection
pressure. Thus, well-tolerated therapeutic alternatives to
treat UTIs and to reduce antimicrobial resistances are
highly warranted.
In 1917, d’Hérelle proposed the use of bacteriophages to
treat bacterial infections. After a colorful episode, the dis-
covery of penicillin by Alexander Fleming declined the
interest for bacteriophages in the Western world rapidly
[7]. At present, bacteriophage therapy is well accepted and
registered in East European and post-Soviet countries like
Georgia, Ukraine, Belarus, and Russia. Lately the use of
bacteriophages as a target therapy against bacterial patho-
gens has gained a renewed interest. Reviews about several
reports of successfully applied bacteriophage therapies for
different medical specializations have been published [7,
8], and the role of bacteriophage as a possible treatment
for difficult to treat microorganisms has been encountered
[9–11]. A recent in vitro study could show excellent re-
sults (i.e. a high lytic activity) of commercially available
bacteriophages for the most common bacterial strains
found in UTIs [12]. Regarding UTIs, several current clin-
ical studies showed positive effects of the use of bacterio-
phage therapy [10, 13–15]. Khawaldeh et al. reported on
the success of adjunctive bacteriophage therapy after
repeated failure of antibiotics alone [10]. An article in Rus-
sian language (http://www.bionow.ru/bnows-1020-2.html)
describes successful treatments for topically applied (i.e.
administrating bacteriophages into the urinary bladder)
bacteriophages for several patients. However, well con-
ducted clinical trials, a defined frame for bacteriophage
therapy in the current Medicinal Product Regulation, and
well-defined, safe bacteriophage preparations are still lack-
ing. In consequence, the use of bacteriophage therapy is
still not accepted as an official treatment against infectious
diseases in the Western world [16, 17].
In line with recommendations of a multi-disciplinary ex-
pert panel on acceptance and re-implementation of bac-
teriophage therapy [11], we therefore designed a
randomized, placebo-controlled, double-blind clinical trial
to assess the efficacy and safety of intravesical bacteriophage
treatment. We hypothesize that intravesical bacteriophage
treatment in patients with UTIs due to E. coli and other
uropathogens, shows a 40% increase in success rate
(normalization of urine culture defined as no evidence of
bacteria, i.e. <104 colony forming units/mL) as compared to
placebo treatment within 7 days. This difference is consid-
ered to be clinically relevant. We also hypothesize that bac-
teriophage treatment is non-inferior to antibiotic treatment
in terms of treatment success rates, with a non-inferiority
margin of 35%.
Methods and design
Study design
This study is a randomized, placebo-controlled, double-
blind trial investigating bacteriophages in UTI treatment.
The study is conducted at the Tzulukidze National Center
of Urology (TNCU), Tbilisi, Georgia. Phage preparations
(i.e. Pyo bacteriophage solution: commercially available
and registered in Georgia) and continuous adaption cycles
during the course of the study, to enhance the treatment
effect, are done at the Eliava Institute of Bacteriophages,
Microbiology, and Virology in Tbilisi (EIBMV), Georgia.
Figure 1 gives an overview of the procedures. Patients
planned for transurethral resection of the prostate are
screened for UTIs at the TNCU. Urine cultures includ-
ing antibiotic sensitivity testing are performed in a dupli-
cate manner. If eligible microorganisms which would
potentially match with the type of bacteriophage present
in Pyo bacteriophage (5 components: Enterococcus spp.,
Escherichia coli, Proteus mirabilis, Pseudomonas aerugi-
nosa, Staphylococcus spp., and Streptococcus spp.) are
detected, urine cultures are then sent for bacteriophage
sensitivity testing to the EIBMV (Fig. 2) [12]. In case of a
positive in-vitro sensitivity testing, concluded within
24 h after receipt of the urine culture, patients will be
asked for study participation. After written informed
consent, patients are randomized in a double-blind fash-
ion to the study treatment arms in a 1:1:1 ratio to re-
ceive either: a) Pyo bacteriophage solution, b) placebo
(sterile bacteriology media with identical color as treat-
ment arm a), or c) antibiotic treatment according to the
antibiotic sensitivity pattern, respectively. Treatment
arms a and b will be double-blind but treatment arm c,
i.e. the control arm representing common clinical prac-
tice, is open label. All treatments are intended for 7 days
starting at the day of surgery (arm c) or one day there-
after (arm a and b). Prior and at the end of treatment
(i.e. after 7 days) or at withdrawal / drop out, urinalysis,
urine culture, bladder and pain diary [18] and an Inter-
national Prostate Symptom Score (IPSS) questionnaire
[19] will be taken. Patients with persistent bacteriuria
will undergo antibiotic treatment according to antibiotic
sensitivity.
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Note: As it is common practice when working with bac-
teriophage cocktails, the Pyo bacteriophage will be sub-
jected to adaptation cycles during the course of the study.
Study population and recruitment
According to the inclusion and exclusion criteria
(Table 1), we will investigate patients planned for trans-
urethral resection of the prostate presenting with UTIs
(defined as ≥104 colony forming units/mL and symp-
toms such as urgency, frequency, and/or dysuria). The
following variables will be considered: age, type of blad-
der emptying, prostate size, urinalysis, bladder and pain
diary, IPSS questionnaire.
Determination of sample size
We are planning a study of independent cases and con-
trols with 1 control per case. Superiority of bacterio-
phage versus placebo treatment: We assume the success
rate among controls to be 0.2. If the true success rate for
experimental subjects is 0.6, we will need to study 27 ex-
perimental and 27 control subjects to be able to reject
the null hypothesis that the success rates for experimen-
tal and control subjects are equal with probability
(power) 0.8. The type I error probability associated with
this test of this null hypothesis is 0.05.
Non-inferiority of bacteriophage versus antibiotic
treatment: We assume the success rate among subjects
Fig. 1 Flow chart of the procedures
Fig. 2 Bacteriophage sensitivity testing to Escherichia coli: The
Escherichia coli culture reacts positively to 12 phages out of 16.
Confluent (complete) lysis can be seen for phages #9, 14 and 16,
overgrown (partial) lysis for phages #4, 6, 7, 8, 10, 11, 12, 13, 15 and
16, respectively
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receiving bacteriophage treatment to be 0.6 and we
accept a non-inferiority margin of 0.35. If the true suc-
cess rate for experimental subjects is 0.95, we will need
to study 27 experimental subjects and 27 control sub-
jects to be able to remain within the non-inferiority mar-
gin with a probability (power) 0.8. The type I error
probability associated with this test of this alternative
hypothesis is 0.05. We will use a continuity-corrected
chi-squared statistic or Fisher’s exact test to evaluate
these hypotheses.
Thus, we will include 27 patients per treatment
group, i.e. 81 patients in total. Withdrawn patients will
be replaced.
Study location and partners
Tzulukidze National Center of Urology, Tbilisi, Georgia:
Patient treatment.
Eliava Institute of Bacteriophages, Microbiology, and
Virology in Tbilisi, Georgia: Phage preparation and
adaptation.
Neuro-Urology, Spinal Cord Injury Center & Research,
University of Zürich, Balgrist University Hospital,
Zürich, Switzerland: Study design, monitoring and statis-
tical support.
Investigations
The patients planned for transurethral resection of the
prostate with a positive urine culture (≥104 colony form-
ing units/mL) of predefined uropathogens sensitive to Pyo
bacteriophage (i.e. Enterococcus spp., Escherichia coli,
Proteus mirabilis, Pseudomonas aeruginosa, Staphylococ-
cus spp., and Streptococcus spp.) and fulfilling the study
inclusion criteria will be included into the study after pro-
viding written informed consent. The patients will be
assessed using bladder and pain diary [18] and an IPSS
questionnaire [19]. The Fig. 1 gives an overview of the
procedures that patients will undergo during the study.
After inclusion, patients will be randomized in a
double-blind fashion to the study treatment arms in a
1:1:1 ratio. Patients of all study arms will undergo mono-
polar transurethral resection of the prostate and inser-
tion of a suprapubic catheter if not already present.
Study arm a) will receive bacteriophage solution (Pyo
bacteriophage) and study arm b) placebo solution (sterile
bacteriology media). Either solution will consist of
20 mL and will have an identical appearance for both
the bacteriophage and the placebo, respectively. An in-
vestigator not involved in the assessment of the clinical
outcome will deliver the solution and teach the patient /
health care provider how to instill the solution into the
bladder. The solution will be instilled using the suprapu-
bic catheter, 2 times per 24 h (i.e. 8.00, 20.00) for 7 days,
starting the first day after surgery. The patients will be
asked to retain the solution in the bladder for approxi-
mately 30–60 min. No antibiotic prophylaxes will be
given to the study treatment arms a and b.
Study arm c) will receive an antibiotic treatment ac-
cording to the antibiotic sensitivity pattern and common
clinical practice.
At the end of treatment (i.e. after 7 days) or at withdrawal
/ drop out, urinalysis, urine culture, bladder and pain diary
[18] and an IPSS questionnaire [19] will be taken. Patients
with persistent UTIs will undergo antibiotic treatment ac-
cording to antibiotic sensitivity for 7 days.
Drop out criteria for patients in the study arm a and b
are fever >38 °C, CRP >100 mg/L, other clinical signs or
symptoms for a systemic infection or withdraw from the
patients. These patients will undergo antibiotic treat-
ment according to antibiotic sensitivity.
Safety
The investigators will inform the patients, the study
monitoring board, and the ethics committee if it be-
comes evident that the disadvantages of participation
Table 1 Study inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age > 18 years
• Urine culture (taken by mid-stream urine; or from the existing trans-
urethral or suprapubic catheter): ≥104 colony forming units/mL of
predefined uropathogens (i.e. Enterococcus spp., Escherichia coli, Pro-
teus mirabilis, Pseudomonas aeruginosa, Staphylococcus spp., and
Streptococcus spp.)
• Uropathogens sensitive to Pyo bacteriophage
• Symptoms: Urgency, frequency, and/or dysuria
• Written informed consent
• Fever >38 °C
• CRP >100 mg/L
• Acute prostatitis
• Concomitant fungal urinary tract infection
• Current antibiotic treatment or antibiotic treatment within the last
7 days (exceptions: subjects with an active catheter associated urinary
tract infection who have received prior antibiotics may be enrolled
provided a minimum of 48 h has elapsed between the last dose of the
prior antibiotic and the time of obtaining the baseline urine specimen.
Subjects receiving current antibiotic prophylaxis for catheter associated
urinary tract infection who present signs and symptoms consistent with
an active new catheter associated infection may be enrolled provided all
other eligibility criteria are met including obtaining a pre-treatment
qualifying baseline urine culture)
• Any rapidly progressing disease or immediately life-threatening illness
including but not limited to: acute hepatic failure, respiratory failure, and
septic shock
• No informed consent
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may be significantly greater than was foreseen in the re-
search proposal. The study will be suspended pending
further review by the study monitoring board, except
insofar as suspension would jeopardize the patients’
health. The investigators will take care that all patients
are kept informed.
Adverse events will be assessed and categorized ac-
cording to the National Cancer Institute Common Ter-
minology Criteria for Adverse Events (CTCAE) version
4 in grade 1 to 5 (http://ctep.cancer.gov/protocolDeve-
lopment/electronic_applications/ctc.htm). All adverse
events will be followed until they have abated, or until a
stable situation has been reached. Depending on the
event, follow-up may require additional tests or medical
procedures as indicated, and/or referral to the general
physician or a medical specialist.
In the case of withdrawal of consent to participate in
the study, all possible efforts will be made to convince the
patient to continue to have safety follow-up evaluations.
In the event one of the following situations arises
among treated patients during the conduct of the study,
the study will be temporarily suspended and a compre-
hensive safety review conducted evaluating if the study
has to be terminated prematurely:
 Any death secondary to rapid unexpected
progression of an underlying medical condition.
 Severe clinical or neurological deterioration in more
than one subject.
 Any other serious adverse event determined by the
study monitoring board to be a reason to suspend
the study.
Study outcome measures
Primary: Success of intravesical treatment, defined as
normalization of urine culture (no evidence of bacteria,
i.e. <104 colony forming units/mL) after 7 days of bac-
teriophage, placebo, or antibiotic treatment.
Secondary: Adverse events, in categorization according
to the National Cancer Institute Common Terminology
Criteria for Adverse Events (CTCAE) version 4 in grade 1
to 5 (http://ctep.cancer.gov/protocolDevelopment/electro-
nic_applications/ctc.htm) during treatment phase.
Tertiary: a) Changes in bladder and pain diary assess-
ment of number of voids, number of leakages, post void
residual, pain assessment using a visual analog scale (0
(no pain) to 10 (strongest possible pain)), b) IPSS items
at baseline versus day 7 under intravesical bacteriophage,
placebo, or antibiotic treatment.
Data analysis
Statistics
Interval scaled variates will be summarized with means
and standard deviations (SD) or medians and interquartile
ranges where appropriate. Dichotomous variates will be
described as ratios and percentages.
Univariate analysis
T-tests will be used to compare means between groups
and chi-squared tests to compare dichotomous variables.
Multivariate analysis
To adjust for unequal distribution of parameters at base-
line, multivariate regression models, linear models in case
of an interval scaled outcome and logistic regression in
case of a dichotomous outcome will be performed.
Discussion
UTIs are among the most prevalent microbial diseases
and their financial burden on society is substantial. The
continuing increase of antibiotic resistance worldwide is
alarming; thus, well-tolerated, highly effective therapeutic
alternatives are urgently needed. Although there is evi-
dence indicating that bacteriophage therapy may be effect-
ive and safe for treating UTIs, the number of investigated
patients is low and there is a lack of randomized con-
trolled trials. Thus, well-designed prospective studies are
urgently needed to draw definitive conclusions in the am-
bitious research field of UTIs. We therefore designed this
first randomized, placebo-controlled, double-blind clinical
trial to assess the efficacy and safety of intravesical bac-
teriophage for treating UTIs. This trial will significantly
influence the future management of UTIs and form a
basis for further studies involving bacteriophages for treat-
ing different bacterial infections. Moreover, the findings of
our research project will provide further stimuli for com-
petent authorities and physicians to use bacteriophages, as
additional tools, in the prevention and treatment of other-
wise virtually untreatable infections. In addition, the trial
is multidisciplinary and will significantly influence all in-
volved disciplines, i.e. urology, microbiology and infec-
tious diseases. It will promote future multidisciplinary,
multicenter approaches and collaborations further im-
proving patients’ medical care and it will also raise the ac-
ceptance to use bacteriophages in western civilizations
and accelerate regulations processes.
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